About Nu Eyne
Nu Eyne is a company based in Seoul (South Korea) founded in 2017. Nu Eyne operates in a competitive market with competitors including CorneaGen, Cellusion, EyeGate, CorNeat Vision and Avedro, among others.
- Headquarter Seoul, South Korea
- SectorsHealthcare
- Email••••••••
- Website nueyne.com
- Social LinkedIn Facebook
- Legal Name New Ain Co., Ltd.
- Annual Revenue$507.07 K (USD)590as on Dec 31, 2024
- Net Profit$7.36 M (USD)221as on Dec 31, 2024
- EBITDA$8.82 M (USD)338as on Dec 31, 2024
People of Nu Eyne
7 people are tracked at Nu Eyne (2 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Pyungkyu Kim | Director, Business Development | Leadership |
Joowan Seo | Director, Product Development | Leadership |
Dohyoung Kim | Executive | Team |
Hwa Sun | Manager, Operations | Team |
Léa Jégo | Marketing Internship | Team |
Kyeongwon Cho | Manager, Research | Team |
Dongseong Lee | Manager, Quality | Team |
Complete people profiles for Nu Eyne
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Nu Eyne
Nu Eyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Cellusion, EyeGate, CorNeat Vision and Avedro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases | |
| biolatticetech.com | 2017 | Philadelphia, United States | – | – | Solutions for tissue repair and restoration are developed. |
Detailed competitors of Nu Eyne
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nu Eyne
The website of Nu Eyne (nueyne.com) receives about 8.2K visits a month.
- Monthly visits8.2K
▲ 125.9% vs previous month
Websites whose visitors overlap most with Nu Eyne. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| todoc.co.kr | 100% | – | – | View details |
Latest news on Nu Eyne
Complete news archive for Nu Eyne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Nu Eyne
10 companies that operate in the same segment as Nu Eyne (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nu Eyne
Nu Eyne was founded in 2017.
Nu Eyne is headquartered in Seoul, South Korea.
Annual revenue of Nu Eyne is $507.07K as on Dec 31, 2024.
Nu Eyne was founded in 2017 and is located in Seoul, South Korea, within the medical devices sector. Devices are developed for treating conditions such as corneal diseases, facial nerve palsy, migraines, ADHD, and overactive bladder. Electrical stimulation is applied in these devices to induce and maintain sleep, support nerve function recovery, and regulate abnormal nervous system activities.
Nu Eyne operates through New Ain Co., Ltd..